ReviewCurrent cardiology reports2026
Sex Differences in Hypertrophic Cardiomyopathy.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review summarizes contemporary evidence regarding sex-based differences in hypertrophic cardiomyopathy (HCM), including disparities in presentation, disease progression, outcomes, and management. RECENT
findingsWomen with HCM are frequently diagnosed later than men and often present with more advanced symptoms, greater left ventricular outflow tract obstruction, worse diastolic dysfunction, and higher heart failure burden. Despite similar rates of ventricular arrhythmias and sudden cardiac death, women experience greater progression to advanced heart failure and poorer quality of life. Emerging evidence suggests that current sex-neutral risk assessment tools may underestimate disease severity in women. Cardiac myosin inhibitors demonstrate similar efficacy across sexes, with some studies suggesting greater symptomatic improvement in women. Persistent disparities in referral patterns, access to specialized care, and representation in clinical trials continue to affect outcomes. Sex-specific differences significantly impact the phenotype, progression, and management of HCM. Greater recognition of these differences is essential to improve individualized care and reduce disparities in outcomes for women with HCM.
Indexed as
Identifiers
42423858What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.